Hematology

Myeloproliferative Neoplasms (MPNs)
[Excluding CML] - Page 2

Indolent & Smoldering Systemic Mastocytosis

Aggressive Systemic Mastocytosis / Mast Cell Leukemia

HEMMPD0044
Phase II/III
BLU-263 in Indolent Systemic Mastocytosis
PI: Shomali
Sponsor: Blueprint Medicines Corporation

HEMMPD0049
Phase II
Multicenter Study of TL-895 in Relapsed / Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
PI: Gotlib
Sponsor: Telios Pharma, Inc.

HEM0061
Phase III
Open-Label 2-Arm Study Evaluating BLU-263 as Monotherapy & in Combo w/ Azacitidine, in KIT Altered Hematologic Malignancies
PI: Gotlib
Sponsor: Blueprint Medicines Corporation

HEMMPD0045
Phase II CCT9486 as a Single Agent in Advanced Systemic Mastocytosis
PI: Gotlib
Sponsor: Cogent Biosciences, Inc.

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunootherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu